Irbaz B. Riaz, M.B.B.S., Ph.D.

Closed for Enrollment

• A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study Of Saruparib (AZD5305) In Combination With Physician’s Choice New Hormonal Agents In Patients With HRRm And Non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) Scottsdale/Phoenix, AZ Jacksonville, FL Rochester, MN

  The purpose of this study is to demonstrate superiority of AZD5305 + physician’s choice NHA relative to placebo + physician’s choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.